[Viferon suppositories in the treatment of influenza in adults].
One hundred and one patients at the age of 18 to 60 years suffering from influenza were observed during increased ratio of the sickness due to the influenza virus types A (H1N1 and H3N2) and B. The diagnosis of influenza was confirmed by the laboratory tests. Viferon was used in the treatment of 35 patients. The randomized double blind placebo-controlled study revealed high therapeutic efficacy ofviferon and its immunomodulating effect on the T-cells, the neutrophil phagocytic activity and the decrease of the levels of the circulating immune complexes. Viferon and arbidol decreased the fever periods and the toxicosis symptoms vs. the placebo. The therapeutic efficacies of viferon and arbidol were on the whole comparable, whereas the clinical findings and the results of the immunological tests were evident of the viferon higher therapeutic and immunomodulating efficacy. No side effects of the drugs were recorded. The tolerability was excellent. Viferon can be recommended for the treatment of influenza in adults.
Gatich
R Z
RZ
Kolobukhina
L V
LV
Vasil'ev
A N
AN
Isaeva
E I
EI
Burtseva
E I
EI
Orlova
T G
TG
Voronina
F V
FV
Kol'tsov
V D
VD
Malinovskaia
V V
VV
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000998:Antiviral Agents / Q000493:pharmacokinetics*; D001205:Ascorbic Acid / Q000494:pharmacology*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype; D053122:Influenza A Virus, H3N2 Subtype; D007251:Influenza, Human / Q000188:drug therapy* / Q000821:virology; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D009824:Ointments; D011994:Recombinant Proteins; D013488:Suppositories; D014810:Vitamin E / Q000494:pharmacology*
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D009824:Ointments; D011994:Recombinant Proteins; D013488:Suppositories; D014810:Vitamin E; D001205:Ascorbic Acid